Fc Receptor (FcR) Antagonist

BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).

C201-0243 is a FcRn antagonist. C201-0243 exhibits antagonistic activity against IgG-FcRn binding with an IC₅₀ of 3.439 nM. C201-0243 can be used in the research of IgG-mediated autoimmune diseases.

SYN1327 is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a K_d of 31 nM for human FcRn at pH 6 and a K_d of 170 nM at pH 7.4. SYN1327 competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 can be used in studies related to IgG-mediated autoimmune diseases.

Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonal antibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma.

SYN1327 acetate is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a K_d of 31 nM for human FcRn at pH 6 and a K_d of 170 nM at pH 7.4. SYN1327 acetate competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acetate acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 acetate can be used in studies related to IgG-mediated autoimmune diseases.

SYN1436 is a selective human neonatal Fc receptor (hFcRn) antagonist with an IC₅₀ of 2.4 nM. SYN1436 binds to hFcRn and inhibits hFcRn-hIgG interaction. SYN1436 can be used for the research of autoimmune diseases.

MDX-220 is a human monoclonal antibody (mAb) targeting FcRn. MDX-220 has anti-tumor activity.

BI-1607 is a humanized monoclonal antibody targeting FcγRIIB/CD32b. BI-1607 selectively blocks inhibitory FcγRIIB signaling, abrogates its inhibitory function, redirects tumor cell-bound antibodies to activating FcγRs, and its modified Fc region prevents the binding of its own Fc segment to FcγRs. BI-1607 reduces αPD-1 trogocytosis, enhances the effector functions of anti-tumor antibodies (including ADCP and ADCC, promotes intratumoral regulatory T cell (Treg) depletion, myeloid cell reprogramming, induction of interferon-γ (IFN-γ) and CXCL10, and increases the number of activated effector CD8⁺ T cells. BI-1607 can be used in research related to colorectal cancer, HER2-positive advanced solid tumors, HER2-positive locally advanced or metastatic breast cancer, and HER2-positive metastatic gastric cancer.